HTR2A-Mediated MMP-9 Suppression Preserves BBB Integrity at Low Doses
🧪 Overview
Trazodone's 5-HT2A antagonism reduces matrix metalloproteinase-9 (MMP-9) expression in cerebral endothelial cells, preserving tight junction proteins (claudin-5, ZO-1) and maintaining BBB integrity. This prevents peripheral inflammatory cell infiltration and reduces parenchymal A-beta accumulation secondary to impaired drainage. However, BBB dysfunction in human AD may be a consequence rather than a cause of neurodegeneration, and the relative contribution of this mechanism to overall disease modification is likely secondary.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Gut Butyrate Deficit<br/>Dysbiosis-Driven SCFA Loss"]
B["HDAC Activity in Endothelium<br/>Chromatin Deacetylation"]
C["CLDN5 Promoter Silencing<br/>Reduced Claudin-5 Expression"]
D["Tight Junction Weakening<br/>BBB Permeability Increase"]
E["Neuroinflammatory Ingress<br/>Peripheral Mediator Entry"]
F["Tributyrin/Butyrate Rescue<br/>HDAC Inhibition"]
G["CLDN5 Re-expression<br/>Barrier Resealing"]
A --> B
B --> C
C --> D
D --> E
F --> G
G -.->|"reverses"| C
G --> D
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HTR2A
No curated PDB or AlphaFold mapping for HTR2A yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HTR2A, MMP-9, CLDN5 (claudin-5), TJP1 (ZO-1) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HTR2A, MMP-9, CLDN5 (claudin-5), TJP1 (ZO-1).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF aged APP/PS1 mice receive chronic low-dose trazodone (5 mg/kg/day via drinking water) for 28 days THEN brain microvessel MMP-9 activity will be reduced by ≥50% compared to vehicle-treated controls, | MMP-9 activity in isolated brain microvessels will decrease by ≥50% (ELISA-based activity assay), and claudin-5 protein levels will be maintained at ≥80% of you | — no observation — | pending | 0.45 |
| IF primary mouse cerebral endothelial cells are pre-treated with a selective 5-HT2A antagonist (e.g., M100907 at 100 nM) for 2 hours prior to IL-1β (10 ng/mL) challenge for 24 hours THEN endothelial c | TEER will remain ≥70% of baseline (indicating preserved barrier function), and MMP-9 concentration in conditioned media will be reduced by ≥60% (ELISA) relative | — no observation — | pending | 0.55 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |